GlaxoSmithKline Pharmaceuticals Limited
GLAXO.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$430.34B
Close$
$2766.60
8.9% upside
Current Fair Value
8.9% upsideUndervalued by 8.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $430.34 Billion |
|---|---|
| Enterprise Value | $430.34 Billion |
| Dividend Yield | $57.00 (2.24%) |
| Earnings per Share | $61.15 |
| Beta | 0.06 |
| Outstanding Shares | 169,406,034 |
Return
| Return on Equity | 47.11% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 40.29 |
|---|---|
| PEG | 256.76 |
| Price to Sales | 10.9 |
| Price to Book Ratio | 19.1 |
| Enterprise Value to Revenue | 10.88 |
| Enterprise Value to EBIT | 29.62 |
| Enterprise Value to Net Income | 40 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$13.90
Average shareholder expectationRevenue Estimate
$10.14 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$16.50
Average shareholder expectationRevenue Estimate
$10.78 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About GlaxoSmithKline Pharmaceuticals Limited
3,103 employees
CEO: Bhushan Akshikar GlaxoSmithKline Pharmaceuticals Limited is a prominent pharmaceutical company involved in the manufacturing, distribution, and sale of medicines across India and internationally. Its extensive product portfolio includes a range of vital ...